Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Common Equity (2019 - 2025)

Historic Common Equity for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $703.6 million.

  • Keros Therapeutics' Common Equity rose 3204.46% to $703.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $703.6 million, marking a year-over-year increase of 3204.46%. This contributed to the annual value of $571.6 million for FY2024, which is 7204.41% up from last year.
  • According to the latest figures from Q3 2025, Keros Therapeutics' Common Equity is $703.6 million, which was up 3204.46% from $706.7 million recorded in Q2 2025.
  • Over the past 5 years, Keros Therapeutics' Common Equity peaked at $728.9 million during Q1 2025, and registered a low of $211.2 million during Q2 2022.
  • Moreover, its 5-year median value for Common Equity was $326.3 million (2023), whereas its average is $385.6 million.
  • In the last 5 years, Keros Therapeutics' Common Equity surged by 109880.16% in 2021 and then crashed by 1037.44% in 2022.
  • Quarter analysis of 5 years shows Keros Therapeutics' Common Equity stood at $243.2 million in 2021, then increased by 14.08% to $277.4 million in 2022, then grew by 19.75% to $332.2 million in 2023, then soared by 72.04% to $571.6 million in 2024, then increased by 23.1% to $703.6 million in 2025.
  • Its Common Equity stands at $703.6 million for Q3 2025, versus $706.7 million for Q2 2025 and $728.9 million for Q1 2025.